康芝药业
(300086)
| 流通市值：29.44亿 | | | 总市值：30.40亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 47,457,968.17 | 92,968,241.64 | 113,185,485.94 | 123,627,683.55 |
| 应收票据及应收账款 | 61,240,622.77 | 62,276,462.27 | 69,064,843.95 | 64,784,702.41 |
| 其中：应收票据 | 6,270,000 | 7,053,112.06 | 620,027.75 | 1,126,464.51 |
| 应收账款 | 54,970,622.77 | 55,223,350.21 | 68,444,816.2 | 63,658,237.9 |
| 预付款项 | 28,798,257.08 | 35,390,195.23 | 23,812,161.44 | 44,087,002.59 |
| 其他应收款合计 | 27,868,385.77 | 68,863,963.39 | 42,210,422.6 | 62,654,202.09 |
| 存货 | 167,845,478 | 175,431,076.57 | 187,328,641.2 | 221,412,440.31 |
| 其他流动资产 | 3,381,547.37 | 5,332,695.84 | 7,473,280.71 | 5,782,987.38 |
| 流动资产合计 | 336,592,259.16 | 440,262,634.94 | 443,074,835.84 | 522,349,018.33 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 4,973,239.88 | 4,973,239.88 | 4,973,239.88 | 5,299,820.44 |
| 投资性房地产 | 243,084,839.8 | 243,084,839.8 | 206,272,603 | 226,006,954.99 |
| 固定资产 | 969,802,540.87 | 984,107,132.1 | 992,215,091.57 | 832,888,959.16 |
| 在建工程 | 15,462,518.85 | 14,111,176.62 | 12,034,555.32 | 162,214,301.92 |
| 生产性生物资产 | - | 17,182.35 | - | 21,775 |
| 使用权资产 | 17,630,168.65 | 17,871,677.8 | 18,113,187.25 | - |
| 无形资产 | 145,830,772.76 | 147,696,426.45 | 139,858,258.34 | 155,466,227.78 |
| 开发支出 | 53,541,380.52 | 50,965,908.82 | 50,965,908.82 | 46,857,139.71 |
| 商誉 | 13,500,000 | 13,500,000 | 13,500,000 | 20,627,224.75 |
| 长期待摊费用 | 28,540,741.01 | 30,865,756.35 | 26,900,856.85 | 29,598,559.2 |
| 递延所得税资产 | 56,033,371.55 | 50,283,550.67 | 50,648,748.85 | 59,346,296.84 |
| 其他非流动资产 | 19,821,659.12 | 15,141,805 | 17,293,263.97 | 26,945,860.19 |
| 非流动资产合计 | 1,568,221,233.01 | 1,572,618,695.84 | 1,532,775,713.85 | 1,565,273,119.98 |
| 资产总计 | 1,904,813,492.17 | 2,012,881,330.78 | 1,975,850,549.69 | 2,087,622,138.31 |
| 流动负债: | | | | |
| 短期借款 | 124,799,882.1 | 161,341,038.05 | 171,084,544.81 | 201,241,038.05 |
| 应付票据及应付账款 | 49,502,465.12 | 51,249,918.4 | 66,256,942.02 | 73,580,840.06 |
| 其中：应付票据 | - | - | - | 5,778,248.8 |
| 应付账款 | 49,502,465.12 | 51,249,918.4 | 66,256,942.02 | 67,802,591.26 |
| 预收款项 | 731,063.65 | 240,000 | 485,928.44 | 240,000 |
| 合同负债 | 36,347,243.25 | 30,048,893.15 | 42,209,406.92 | 11,163,045.82 |
| 应付职工薪酬 | 7,730,244.97 | 7,919,242.48 | 11,180,823.52 | 8,054,136.4 |
| 应交税费 | 10,684,244.15 | 8,628,112.64 | 11,415,974.24 | 15,948,349.78 |
| 其他应付款合计 | 129,725,026.87 | 142,357,298.34 | 76,596,646.73 | 73,574,376.78 |
| 一年内到期的非流动负债 | 88,446,610.84 | 108,876,610.84 | 110,969,527.93 | 90,440,000 |
| 其他流动负债 | 4,721,457.43 | 3,903,647.3 | 5,480,752.85 | 1,448,548.8 |
| 流动负债合计 | 452,688,238.38 | 514,564,761.2 | 495,680,547.46 | 475,690,335.69 |
| 非流动负债: | | | | |
| 长期借款 | 233,065,000 | 239,039,265.69 | 210,000,000 | 246,059,027.78 |
| 租赁负债 | 19,012,665.87 | 18,830,818.59 | 18,648,971.31 | - |
| 递延收益 | 55,394,434.07 | 50,870,287.24 | 51,625,213.59 | 50,440,754.38 |
| 递延所得税负债 | 34,456,113.55 | 34,516,490.84 | 34,576,868.2 | 33,143,393.95 |
| 非流动负债合计 | 341,928,213.49 | 343,256,862.36 | 314,851,053.1 | 329,643,176.11 |
| 负债合计 | 794,616,451.87 | 857,821,623.56 | 810,531,600.56 | 805,333,511.8 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 455,124,411 | 455,124,411 | 455,124,411 | 455,124,411 |
| 资本公积 | 842,991,008.41 | 842,991,008.41 | 842,991,008.41 | 859,943,390.87 |
| 其他综合收益 | 51,719,218.63 | 51,729,678.49 | 51,732,777.71 | 51,975,089.8 |
| 盈余公积 | 54,941,795.33 | 54,941,795.33 | 54,941,795.33 | 54,941,795.33 |
| 未分配利润 | -318,949,298.8 | -274,559,275.7 | -264,867,579.44 | -171,389,850.19 |
| 归属于母公司股东权益合计 | 1,085,827,134.57 | 1,130,227,617.53 | 1,139,922,413.01 | 1,250,594,836.81 |
| 少数股东权益 | 24,369,905.73 | 24,832,089.69 | 25,396,536.12 | 31,693,789.7 |
| 股东权益合计 | 1,110,197,040.3 | 1,155,059,707.22 | 1,165,318,949.13 | 1,282,288,626.51 |
| 负债和股东权益合计 | 1,904,813,492.17 | 2,012,881,330.78 | 1,975,850,549.69 | 2,087,622,138.31 |
| 公告日期 | 2025-08-28 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |